Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Dow
UBS
Mallinckrodt
Teva
Chubb
Cantor Fitzgerald
Express Scripts
US Army
Citi

Generated: January 19, 2018

DrugPatentWatch Database Preview

Merck Company Profile

« Back to Dashboard

Summary for Merck
International Patents:1505
US Patents:76
Tradenames:104
Ingredients:86
NDAs:126

Drugs and US Patents for Merck

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck CANCIDAS caspofungin acetate POWDER;IV (INFUSION) 021227-001 Jan 26, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER cefoxitin sodium INJECTABLE;INJECTION 050581-003 Sep 20, 1984 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-002 Feb 2, 2012 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUVIA sitagliptin phosphate TABLET;ORAL 021995-001 Oct 16, 2006 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme JANUVIA sitagliptin phosphate TABLET;ORAL 021995-001 Oct 16, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-002 Nov 10, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme DUTREBIS lamivudine; raltegravir potassium TABLET;ORAL 206510-001 Feb 6, 2015 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Merck

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck DOLOBID diflunisal TABLET;ORAL 018445-001 Apr 19, 1982 ➤ Subscribe ➤ Subscribe
Merck PEPCID PRESERVATIVE FREE famotidine INJECTABLE;INJECTION 019510-004 Nov 4, 1986 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Subscribe ➤ Subscribe
Merck FOSAMAX alendronate sodium SOLUTION;ORAL 021575-001 Sep 17, 2003 ➤ Subscribe ➤ Subscribe
Merck VIOXX rofecoxib SUSPENSION;ORAL 021052-002 May 20, 1999 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme DULERA formoterol fumarate; mometasone furoate AEROSOL, METERED;INHALATION 022518-002 Jun 22, 2010 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme HYZAAR hydrochlorothiazide; losartan potassium TABLET;ORAL 020387-002 Nov 10, 1998 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme CLARINEX desloratadine TABLET, ORALLY DISINTEGRATING;ORAL 021312-001 Jun 26, 2002 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ➤ Subscribe ➤ Subscribe
Merck Sharp Dohme SINEMET carbidopa; levodopa TABLET;ORAL 017555-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MERCK drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Oral Suspension 125 mg/Kit ➤ Subscribe 11/23/2016
➤ Subscribe Injection 18 mg/mL, 16.7 mL vials ➤ Subscribe 11/24/2015
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 5/1/2015
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 4/14/2015
➤ Subscribe Delayed-release Tablets 100 mg ➤ Subscribe 6/16/2014
➤ Subscribe Injection 1 g/vial ➤ Subscribe 6/20/2013
➤ Subscribe Tablets 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg ➤ Subscribe 11/6/2012
➤ Subscribe Extended-release Tablets 100 mg/1000 mg ➤ Subscribe 10/22/2012
➤ Subscribe Tablets 100 mg/10 mg and 100 mg/40 mg ➤ Subscribe 6/25/2012
➤ Subscribe Tablets 100 mg/10 mg and 100 mg/40 mg ➤ Subscribe 6/19/2012
➤ Subscribe Extended-release Capsules 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 3/16/2012
➤ Subscribe Injection 115 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Injection 150 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Tablets 400 mg ➤ Subscribe 10/12/2011
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2/28/2011
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 10/18/2010
➤ Subscribe Tablets 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 10/18/2010
➤ Subscribe Nasal Spray 50 mcg/ Spray ➤ Subscribe 8/7/2009
➤ Subscribe For Injection 50 mg/vial and 70 mg/vial ➤ Subscribe 6/26/2009
➤ Subscribe Capsule 40 mg, 80 mg and 125 mg ➤ Subscribe 11/3/2008
➤ Subscribe Capsules 140 mg and 180 mg ➤ Subscribe 3/24/2008
➤ Subscribe Tablets 70 mg/2800 IU and 70 mg/5600 IU ➤ Subscribe 11/20/2007
➤ Subscribe Oral Solution 70 mg/75 mL ➤ Subscribe 9/7/2007
➤ Subscribe Tablets 10 mg ➤ Subscribe 2/20/2007
➤ Subscribe Chewable Tablets 4 mg and 5 mg ➤ Subscribe 12/26/2006
➤ Subscribe Tablets 5 mg ➤ Subscribe 6/21/2006
➤ Subscribe Orally Disintegrating Tablets 2.5 mg and 5 mg ➤ Subscribe 6/21/2006
➤ Subscribe Tablets 100 mg/12.5 mL ➤ Subscribe 4/4/2006
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2/17/2006
➤ Subscribe Ophthalmic Solution 2% ➤ Subscribe 10/11/2005
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 9/2/2004
➤ Subscribe Topical Solution (Lotion) 0.10% ➤ Subscribe 6/10/2004
➤ Subscribe Tablets 50 mg/12.5 mg and 100 mg/25 mg ➤ Subscribe 5/24/2004
Premature patent expirations for MERCK

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for Merck

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,654 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors ➤ Subscribe
9,090,661 Inhibitors of hepatitis C virus replication ➤ Subscribe
9,044,424 Methods of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
5,714,490 Tetrahydrofuran antifungals ➤ Subscribe
6,465,443 Method for inhibiting bone resorption ➤ Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
5,693,626 Tetrahydrofuran antifungals ➤ Subscribe
7,012,066 Peptides as NS3-serine protease inhibitors of hepatitis C virus ➤ Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Subscribe
7,375,137 Methods of treating cancer with HDAC inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Merck Drugs

Supplementary Protection Certificates for Merck Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00506 Netherlands ➤ Subscribe PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROATMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
C0004 France ➤ Subscribe PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
00095 Netherlands ➤ Subscribe PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0080004 00019 Estonia ➤ Subscribe PRODUCT NAME: JANUMET - SITAGLIPTIIN / METFORMIINVESINIKKLORIID
C/GB04/011 United Kingdom ➤ Subscribe PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
1506211/02 Switzerland ➤ Subscribe PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015
C0028 France ➤ Subscribe PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124
30/2008 Austria ➤ Subscribe PRODUCT NAME: RALTEGRAVIR ODER DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE DAS KALIUMSALZ
C/GB08/040 United Kingdom ➤ Subscribe PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
2014 00062 Denmark ➤ Subscribe PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091005
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Deloitte
Dow
Farmers Insurance
Johnson and Johnson
Baxter
Teva
Chubb
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot